Cencora, Inc. (COR)
Health Care · Health Care Distributors · US stock · S&P 500 component
$340.92
▼ -0.49 (0.14%)
Fair valueOvervalued
$200 −41.2% to fair value
$100fair band $120–$281$301
Day's range
$339.01 – $343.31
52-week range
$243.78 – $375.33
About Cencora, Inc.
Cencora is a pharmaceutical distributor that buys medicines and other health products from manufacturers and delivers them to pharmacies, hospitals, clinics and physician practices. It also provides services to drugmakers, including logistics, specialty drug support and consulting, and it has operations in Europe and other regions. Its profits are earned on small spreads over very large sales volumes, so scale, contracts and efficient logistics are central.
Trailing twelve-month revenue stands at $332.8 billion, while revenue grew by 10.4% a year over the past three years. Return on invested capital is 19%, alongside an operating margin of 0.9%. Net debt is 2.2 times EBITDA. The company pays a dividend, and the yield is 0.7%. On the X-Ray Score, it is rated 52 out of 100. The figures are a snapshot of reported results rather than a forecast.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $243.78 – $375.33Volume 1,978,900Daily, split-adjusted
Vitals
Market cap$66.1B
52-week range$243.78 – $375.33
Volume (last day)1,978,900
P/E (TTM)25.3
EBIT / EV yield4.0%
Free-cash-flow yield6.1%
Dividend yield0.7%
Revenue (TTM)$332.8B
Net income (TTM)$2.6B
Operating margin0.9%
Return on capital18.6%
Debt incl. leases$11.7B
Cash & securities$2.8B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$200model spread $181 – $214
Overvalued
−41.2% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Multiples use through-the-cycle earnings (0.38x of the last twelve months)
Peak-cycle earnings: the current operating margin is more than 1.5x its 7-year average, so the fair value range is widened
Price $341
Undervalued < $120Fair $120 – $281Overvalued > $281
10-year DCF (market-scaled)
$304
Peer multiples
$141
Earnings power floor (not blended)
$94
Fundamentals-adjusted multiple
$156
Growth the price implies
16.3%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
45/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield4.0%
Free-cash-flow yield6.1%
Fair value vs price0.6×
Growth
Fair
62/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)10.4%
EPS growth (3y)-0.3%
Growth consistency100%
Profitability
Weak
45/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital18.6%
Operating margin0.9%
Gross profitability15.8%
Financial health
Weak
40/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score6 / 9
Net debt / EBITDA2.2×
Interest coverNo interest cost
Dividends
Fair
57/100
Dividend is typical for its sector.
See the numbers →
Dividend yield0.7%
Dividends vs free cash flow11%
Dividend growth3.7%
Quarterly results: last 6 quarters
+10.3%
Mar '25
+8.7%
Jun '25
+5.9%
Sep '25
+5.5%
Dec '25
+3.8%
Mar '26
+5.1%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $84.8B, diluted EPS $3.94.
Compare with peers
MCK Mckesson Corp55 CAH Cardinal Health Inc52 HSIC Henry Schein Inc42Other Health Care Distributors companies by X-Ray Score.
Fundamentals checklist
● 5 Good · ● 4 Average · ● 7 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAAverage
Interest coverGood
Valuation
Fair value vs priceBad
EBIT / EV yieldAverage
Profitability
Return on invested capitalAverage
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 44/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Operating income | $2.4B | $2.4B | $2.3B | $2.2B | $2.6B |
| Net income | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B |
| Operating cash flow | $2.7B | $2.7B | $3.9B | $3.5B | $3.9B |
| Operating margin | 1.1% | 1.0% | 0.9% | 0.7% | 0.8% |
| Free cash flow | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
| Diluted EPS | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
12 bullish · 0 neutral · 4 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 326.7 | Bullish |
| EMA 10 | 328.9 | Bullish |
| SMA 20 | 317.9 | Bullish |
| EMA 20 | 323.3 | Bullish |
| SMA 50 | 320.2 | Bullish |
| EMA 50 | 317.9 | Bullish |
| SMA 100 | 305.8 | Bullish |
| EMA 100 | 313.7 | Bullish |
| SMA 200 | 316.6 | Bullish |
| EMA 200 | 311.7 | Bullish |
Oscillators (daily)
| RSI (14) | 70.06 | Bearish |
| MACD (12, 26) | 5.33 | Bullish |
| Momentum (12) | 13.55 | Bullish |
| Stochastic %K (14) | 91.00 | Bearish |
| Williams %R (14) | -9.00 | Bearish |
| CCI (20) | 168.3 | Bearish |
Pivot points (classic, last session)
S3 334.5 | S2 336.8 | S1 338.8 | Pivot 341.1 | R1 343.2 | R2 345.4 | R3 347.5 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.40 USD
Yield on today's price
0.70%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | 0.6000 |
| 15 May 2026 | 0.6000 |
| 13 Feb 2026 | 0.6000 |
| 14 Nov 2025 | 0.6000 |
| 15 Aug 2025 | 0.5500 |
| 16 May 2025 | 0.5500 |
| 14 Feb 2025 | 0.5500 |
| 15 Nov 2024 | 0.5500 |
| 9 Aug 2024 | 0.5100 |
| 9 May 2024 | 0.5100 |
| 8 Feb 2024 | 0.5100 |
| 10 Nov 2023 | 0.5100 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
COR SEC filings
25 Sep 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
14 Aug 2026
8-KSEC EDGAR
Director or officer change
12 Aug 2026
8-KSEC EDGAR
Regulation FD disclosure
5 Aug 2026
10-QSEC EDGAR
Quarterly report
5 Aug 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
5 Aug 2026
8-KSEC EDGAR
Entered a material agreement
15 Jun 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
29 May 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.